Appendix Table C22. Clinical renal outcomes (outcomes part C), ACEI plus ARB versus ACEI or ARB trials

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **End-stage Renal Disease****n/N (%)** | **Doubling of Serum Creatinine n/N (%)** | **Halving of GFR****n/N (%)** | **Progression from Micro- to Macroalbuminuria****n/N (%)** | **Composite Renal Outcome n/N (%)#** |
| ***ACEI plus ARB versus ACEI trials (n=5)*** |
|  | **ACEI+ARB** | **ACEI** | **ACEI+ARB** | **ACEI** | **ACEI+ARB** | **ACEI** | **ACEI+ARB** | **ACEI** | **ACEI+ARB** | **ACEI** |
| Sengul, 200620 |  |  |  |  |  |  | 0/96(0) | 0/48(0) |  |  |
| Menne, 200819VALERIA |  |  |  |  |  |  | 1/43(2.5) | 3/47(6.4) |  |  |
| Kanno, 200644 | 2/45(4.4) | 2/45(4.4) | 0/45(0) | 7/45(15.6) |  |  |  |  |  |  |
| Mehdi, 200945 |  |  | \*\*NR | \*\*NR |  |  |  |  |  |  |
| Anand, 200946 |  |  |  |  |  |  |  |  |  |  |
| ***ACEI plus ARB versus ARB trials (n=3)*** |
|  |  |  | **ACEI+ARB** | **ARB** |  |  | **ACEI+ARB** | **ARB** | **ACEI+ARB** | **ARB** |
| Sengul, 200620 |  |  |  |  |  |  | 0/96(0) | 0/48(0) |  |  |
| Menne, 200819 |  |  |  |  |  |  | 1/43(2.5) | 3/43(7.1) |  |  |
| ***ACEI plus ARB versusACEI or ARB trials (monotherapy) (n=1)*** |
|  | **ACEI+ARB** | **Mono** | **ACEI+ARB** | **Mono** | **ACEI+ARB** | **Mono** | **ACEI+ARB** | **Mono** | **ACEI+ARB** | **Mono** |
| Tobe 201135Mann, 200818ON-TARGET | *Chronic dialysis*31/2943(1.1) | *Chronic dialysis*53/5990(0.9) | 86/2943(2.9) | 140/5990(2.3) |  |  |  |  | 104/2943(3.5) | 173/5990(2.9) |

ACEI = angiotensin convertng enzyme; ARB = angiotensin receptor blocker; GFR = glomerular filtration rate
#See composite renal outcome definitions table
\*Reported for the overall participants but not for the CKD subgroup
\*\*Reported 50% increase in serum creatinine in 13/26 (50%) of ACEI+ARB group and 10/27 (37%) of ACEI group
†Had microalbuminuria at baseline; N based on back calculation using percentage with progression